HEALTH
Long-Term Tirzepatide Demonstrates Benefits in Patients With CKD, Obesity, and HFpEF – Pharmacy Times
- Long-Term Tirzepatide Demonstrates Benefits in Patients With CKD, Obesity, and HFpEF Pharmacy Times
- KOL Views Q&A: Zepbound boosts CV outcomes in HFpEF patients regardless of kidney function FirstWord Pharma
- Positive Results for Tirzepatide in Those With the Cardiovascular-Kidney-Metabolic Triad | ACC 2025 Managed Healthcare Executive
- ACC 25: tirzepatide influences clinical trajectory of patients with HFpEF and obesity Yahoo Finance
- Tirzepatide improves outcomes in HFpEF, obesity regardless of kidney function Healio
Source link
